Effects of antioxidant on emphysema and mucin hypersecretion in overlap syndrome model
- 주제(키워드) Antioxidant , Overlap syndrome , Emphysema , Mucus Hypersecretion
- 발행기관 고려대학교 대학원
- 지도교수 심재정
- 발행년도 2011
- 학위수여년월 2011. 2
- 학위구분 박사
- 학과 일반대학원 의학과
- 세부전공 내과학 전공
- 원문페이지 39 p
- 실제URI http://www.dcollection.net/handler/korea/000000024488
- 본문언어 영어
- 제출원본 000045635202
초록/요약
Both bronchial asthma and chronic obstructive pulmonary disease (COPD) are characterized by airflow obstruction and chronic persistent inflammatory process, but the nature of the inflammation, clinical manifestation and response to therapy differ markedly between these diseases. In clinical setting, it is more likely that both of these very common diseases may occur concurrently in some patients and such conditions have been defined as overlap syndrome. To evaluate antioxidant effect of Epigallocatechin-3-gallate (EGCG) on development of emphysema and mucus hypersecretion in asthma, smoking and overlap syndrome models, we used the senescence accelerated mouse (SAM). We also aimed to analyze the effects of EGCG on mucin production stimulated by cigarette smoking, IL-13 and TNF-α in NCI-H292 cell lines. In vitro studies, EGCG inhibited MUC5AC mucin production induced by cigarette smoking, pro-inflammatory cytokine (TNF-α) and Th2 cytokine (IL-13) in NCI-H292 cells in a dose-dependent manner (p <0.05). In vivo studies, the mean linear intercept (MLI) was increased in smoking (34.35 ± 3.87㎛, p = 0.06) and overlap syndrome groups (29.37 ± 0.90㎛, p = 0.025). The destructive index (DI) was also increased in smoking (25.30 ± 3.86%, p = 0.06) and overlap syndrome group (22.00 ± 2.49%, p = 0.09). EGCG inhibited development of emphysema in smoking (DI = 20.23 ± 1.78%, p = 0.016 compared with smoking control group) and overlap syndrome model (DI = 18.44 ± 1.93%, p = 0.036 compared with overlap control group). Treatment of EGCG also inhibited goblet cell metaplasia in smoking (8.76 ± 2.88% of epithelium, p = 0.010 compared with smoking control group), asthma (20.40 ± 12.93% of epithelium, p = 0.045 compared with asthma control group), and overlap syndrome groups (17.08 ± 2.78% of epithelium, p = 0.042 compared with overlap control group). In this study, we developed asthma model and overlap syndrome model in SAM for the first time. And our data indicate that EGCG can suppress development of emphysema and mucus hypersecretion in overlap syndrome model, which maybe useful tool to investigate both pathogenesis and the effects of therapeutic trials for overlap syndrome.
more목차
Ⅰ. Introduction 1
Ⅱ. Materials and Methods 4
Ⅲ. Results 11
Ⅳ. Discussion 15
Ⅴ. References 20
